HRT for Women: Understanding Menopause and Beyond

Hormonal changes during perimenopause and menopause can affect far more than the menstrual cycle. Hot flashes, night sweats, disrupted sleep, vaginal dryness, painful intercourse, mood changes, and other symptoms can significantly affect quality of life.

For appropriately selected women, hormone replacement therapy (HRT)—more precisely called menopausal hormone therapy (MHT) or hormone therapy (HT)—can be one of the most effective treatments available.

Modern hormone therapy is not simply about “replacing hormones” to restore youthful hormone levels. The goal is to identify symptoms that may be related to menopause, determine whether hormone treatment is medically appropriate, and select a treatment whose expected benefits outweigh its risks for the individual patient.

At Ask Dr. Hu, we take this individualized approach when evaluating women for hormone replacement therapy in Arizona.

What Happens to Hormones During Perimenopause and Menopause?

Menopause is a normal biological transition rather than a disease.

Perimenopause is the period leading up to menopause, during which ovarian hormone production becomes increasingly variable. Estrogen levels may rise and fall unpredictably, progesterone exposure may change as ovulation becomes less consistent, and menstrual cycles often become irregular.

Menopause is reached after 12 consecutive months without a menstrual period when there is no other explanation for the absence of menstruation. It most commonly occurs between approximately ages 45 and 55.

Hormonal fluctuations can begin years before the final menstrual period, which is why women do not need to wait until they are officially postmenopausal before discussing treatment.

Common symptoms during the menopause transition may include hot flashes, night sweats, difficulty sleeping, vaginal dryness, discomfort with intercourse, changes in urinary symptoms, mood changes, difficulty concentrating, headaches, and changes in sexual function.

Some women experience very few symptoms. Others experience symptoms severe enough to interfere with sleep, work, relationships, exercise, or daily functioning.

Treatment should therefore be based on the individual—not simply on age.

What Is HRT for Women?

Hormone replacement therapy for women typically involves estrogen, a progestogen such as progesterone when indicated, or a combination of hormones.

You can read a broader introduction in What Is Hormone Replacement Therapy?.

The two main approaches to menopausal hormone therapy are systemic hormone therapy and local vaginal hormone therapy.

Systemic estrogen circulates throughout the body and may be delivered through tablets, skin patches, gels, sprays, or certain vaginal rings. Systemic treatment is generally used when a woman needs relief from symptoms such as hot flashes and night sweats.

Low-dose vaginal estrogen is applied primarily to the vaginal and surrounding tissues. It is particularly useful for genitourinary syndrome of menopause, including vaginal dryness, irritation, painful intercourse, and certain urinary symptoms. Systemic absorption with appropriately dosed local vaginal estrogen is substantially lower than with systemic therapy.

The best option depends on what symptoms are being treated, whether the uterus is present, the woman's health history, risk factors, preferences, and treatment goals.

Estrogen Is the Main Treatment for Many Menopause Symptoms

Estrogen is the primary hormone responsible for relieving many classic menopausal symptoms.

Systemic estrogen therapy is the most effective treatment for bothersome vasomotor symptoms such as hot flashes and night sweats and can also help prevent menopause-associated bone loss.

Estrogen may be administered through several routes.

Oral estrogen is convenient and effective but passes through the liver before reaching the systemic circulation. Transdermal estrogen, such as a patch, gel, or spray, delivers estrogen through the skin and avoids first-pass hepatic metabolism.

Route matters because different formulations may have different effects on clotting factors, lipids, and other physiologic processes. Observational evidence suggests transdermal estrogen may carry a lower risk of venous thromboembolism than oral estrogen, although direct randomized comparisons remain limited.

There is no single estrogen formulation that is best for every woman.

Why Is Progesterone Often Used With Estrogen?

Whether progesterone or another progestogen is needed depends largely on whether a woman still has her uterus.

Systemic estrogen stimulates the endometrium, or lining of the uterus. If estrogen is taken without adequate endometrial protection in a woman with an intact uterus, the risk of endometrial hyperplasia and endometrial cancer increases.

For this reason, women with a uterus who take systemic estrogen generally require adequate progesterone or another progestogen for endometrial protection.

Women who have undergone hysterectomy can often use estrogen without a progestogen, although individual circumstances can modify treatment decisions.

Low-dose vaginal estrogen used specifically for genitourinary symptoms generally does not require the addition of a progestogen at recommended doses. Any new or unexplained postmenopausal bleeding, however, warrants medical evaluation.

What Symptoms Can HRT Help?

Hormone therapy is best established for a specific group of menopause-related concerns rather than as a general treatment for every symptom that develops in middle age.

Hot Flashes and Night Sweats

Hot flashes and night sweats—collectively known as vasomotor symptoms—are among the most common reasons women seek menopause treatment.

Hormone therapy remains the most effective treatment for bothersome vasomotor symptoms.

Reducing nighttime symptoms can also improve sleep when hot flashes or night sweats are responsible for repeated awakenings.

Vaginal Dryness and Painful Intercourse

Declining estrogen can gradually change the tissues of the vulva, vagina, urethra, and bladder.

This collection of symptoms is called genitourinary syndrome of menopause, or GSM.

Symptoms can include vaginal dryness, burning, irritation, decreased lubrication, pain with sexual activity, urinary urgency, discomfort with urination, and recurrent urinary tract infections.

If vaginal or urinary symptoms are the primary concern without significant hot flashes or other systemic symptoms, low-dose vaginal estrogen may be preferable to systemic hormone therapy.

Unlike hot flashes, GSM frequently becomes more persistent rather than simply disappearing with time.

Bone Health

Loss of estrogen accelerates bone turnover and contributes to declining bone density after menopause.

Systemic hormone therapy can prevent bone loss and reduce fracture risk while it is being used. Hormone therapy is FDA-approved for prevention of postmenopausal osteoporosis in appropriate circumstances, although other osteoporosis medications may be preferred when treatment of established osteoporosis is the primary objective.

Bone health becomes particularly important for women who experience menopause substantially earlier than average.

Sleep and Quality of Life

Hormone therapy is not a universal sleep medication, but women whose sleep disruption is being driven by night sweats and other menopausal symptoms often experience improvement when those symptoms are effectively treated.

The same principle applies to fatigue, concentration problems, and mood. These symptoms may improve when menopause-related sleep disruption or vasomotor symptoms improve, but they can also have many other causes.

Thyroid disease, anemia, depression, anxiety, sleep apnea, medication effects, nutritional deficiencies, and other medical problems should not automatically be attributed to menopause.

Who Is Most Likely to Benefit From Menopausal Hormone Therapy?

For healthy women with bothersome menopause symptoms and no contraindications, the overall benefit-risk profile of systemic hormone therapy is generally most favorable when treatment is initiated before age 60 or within approximately 10 years of menopause onset.

This does not mean a woman automatically qualifies for hormone therapy because she is younger than 60.

It also does not mean hormone therapy suddenly becomes prohibited at age 60.

Instead, age, time since menopause, symptoms, cardiovascular risk, cancer history, clotting risk, uterine status, medications, and other health factors all influence the decision.

If you are wondering whether treatment may be appropriate, see Am I a Candidate for Hormone Replacement Therapy?.

HRT During Perimenopause

Hormone therapy can sometimes be used before a woman's menstrual periods have completely stopped.

Perimenopausal women may experience significant hot flashes, night sweats, sleep disruption, or other symptoms even while continuing to menstruate.

Treatment can be more complicated during this stage because ovarian hormone production is still fluctuating, pregnancy may still be possible, menstrual bleeding patterns are changing, and menopausal hormone therapy itself is not contraception.

Some women who still need contraception may be better suited to certain hormonal contraceptive strategies, while others may use menopausal hormone therapy combined with appropriate endometrial protection.

The choice should be individualized according to symptoms, bleeding patterns, contraceptive needs, medical history, and risk factors.

Do Women Need Hormone Blood Tests Before Starting HRT?

This is an area where context matters.

During perimenopause, estrogen and follicle-stimulating hormone levels can vary considerably, which means a single blood measurement may not accurately represent what is happening over time.

Typical menopause in an appropriately aged woman can often be recognized clinically from menstrual history and symptoms rather than from an extensive hormone panel.

Laboratory testing becomes more useful when the diagnosis is uncertain, symptoms are atypical, menopause occurs unusually early, another endocrine condition is suspected, or a particular treatment requires monitoring.

Other tests may also be appropriate depending on the clinical picture, such as thyroid studies, blood counts, metabolic testing, or evaluation for other causes of the patient's symptoms.

For a more detailed explanation, read Hormone Testing: Blood, Saliva & Urine Tests.

The important principle is that hormone therapy should not be prescribed solely to move laboratory values toward a predetermined “optimal” number.

What Are the Potential Risks of HRT?

Hormone therapy is neither universally dangerous nor universally safe.

Risk depends on the specific hormone, dose, route of administration, whether a progestogen is used, the woman's age, time since menopause, duration of treatment, and underlying health risks.

Blood Clots

Oral systemic estrogen can increase the risk of venous thromboembolism in some women.

Available observational evidence suggests transdermal estrogen may have a lower thrombotic risk than oral therapy, making route of administration an important consideration in individualized prescribing.

Cardiovascular Disease and Stroke

The relationship between hormone therapy and cardiovascular health depends heavily on when treatment is initiated and on the patient's baseline cardiovascular risk.

Women beginning systemic hormone therapy after age 60 or more than approximately 10 years after menopause generally have higher absolute cardiovascular, stroke, and thromboembolic risks than women starting earlier in the menopause transition.

Hormone therapy should therefore not be prescribed simply as a medication to prevent cardiovascular disease.

Breast Cancer

Breast cancer risk requires a more nuanced discussion than either “HRT causes breast cancer” or “HRT does not cause breast cancer.”

Risk differs between estrogen-alone therapy and estrogen-progestogen therapy, and duration of treatment matters. The Menopause Society notes that breast cancer risk associated with combined estrogen-progestogen therapy becomes detectable after several years of use in available data, whereas estrogen-alone therapy has a different risk profile.

Personal breast cancer history, family history, genetic risk, previous biopsies, breast density, alcohol intake, age, and other factors should therefore be considered as part of an individualized discussion.

Systemic hormone therapy is generally not recommended for women with a history of estrogen-sensitive breast cancer except in unusual circumstances requiring multidisciplinary shared decision-making.

Endometrial Cancer

The primary preventable endometrial risk occurs when systemic estrogen is used without adequate progestogen protection in a woman who still has a uterus.

Appropriate progesterone or progestogen therapy substantially changes this risk and is why uterine status must be considered when creating an HRT regimen.

Who Should Generally Avoid Systemic HRT?

Systemic oral or transdermal hormone therapy may be contraindicated or require specialist-level evaluation in women with certain medical histories.

Important considerations include unexplained vaginal bleeding, active or significant liver disease, prior estrogen-sensitive cancer, previous coronary heart disease, myocardial infarction, stroke, venous thromboembolism, or a strong personal or inherited risk of thromboembolic disease.

These considerations apply primarily to systemic therapy. Low-dose vaginal estrogen has a very different degree of systemic exposure and may sometimes remain an option when systemic estrogen is inappropriate.

Women with a history of breast cancer or other complex medical conditions should make these decisions with the clinicians managing those conditions.

An Important 2026 FDA Update on Menopause Hormone Therapy

Understanding hormone therapy also requires understanding how its safety messaging has changed.

Following the original Women's Health Initiative findings in the early 2000s, class-wide boxed warnings were applied to menopausal estrogen and estrogen-progestogen products.

In November 2025, after reviewing subsequent evidence and recognizing important differences between the older WHI study population and women who commonly begin treatment closer to menopause, the FDA requested significant labeling revisions.

The FDA asked manufacturers to remove boxed-warning language concerning cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy products. For systemic estrogen-alone products, the boxed warning concerning endometrial cancer remains. Cardiovascular and breast cancer risk information has not simply disappeared; relevant information remains in other portions of systemic-product prescribing information.

In February 2026, the FDA approved the first six products with the revised labeling, with additional manufacturers having submitted label changes.

This update is important because it moves menopause care away from applying one generalized warning to every formulation and every woman.

It does not mean that hormone therapy is risk-free or appropriate for everyone.

Individualized risk assessment remains essential.

What Does “Bioidentical HRT” Mean?

The term bioidentical hormone is frequently misunderstood.

A bioidentical hormone has the same molecular structure as a hormone naturally produced by the human body. FDA-approved estradiol and micronized progesterone products can therefore be bioidentical.

Bioidentical does not automatically mean compounded.

Custom-compounded hormone preparations may be necessary in certain unusual circumstances, such as when an appropriate FDA-approved dosage or formulation is not available or a patient has an allergy to an ingredient in a commercially manufactured product.

However, compounded preparations do not undergo the same FDA review for manufacturing consistency, dosing, safety, and efficacy as approved pharmaceutical products. Professional organizations therefore generally favor FDA-approved hormone preparations when an appropriate option exists.

Saliva or urine hormone testing also should not be used routinely to customize menopausal hormone doses based on supposed individualized “optimal” hormone targets.

What About Testosterone for Women?

Testosterone is sometimes discussed as part of women's hormone therapy, but its role is much narrower than estrogen's role in menopause treatment.

Current evidence supports carefully dosed testosterone therapy primarily for appropriately evaluated postmenopausal women with hypoactive sexual desire disorder, meaning persistent low sexual desire that causes meaningful distress after other contributing factors have been addressed.

Testosterone is not currently considered an evidence-based general treatment for menopause-related fatigue, brain fog, weight gain, mood changes, osteoporosis, or normal aging.

Evaluation of sexual concerns should first consider factors such as vaginal discomfort, medications, depression or anxiety, relationship factors, sleep problems, medical conditions, and other possible contributors.

When testosterone is used in women, avoiding excessive dosing is particularly important.

What About Early Menopause or Primary Ovarian Insufficiency?

The risk-benefit discussion is different when ovarian estrogen production is lost substantially earlier than the usual age of menopause.

Women with primary ovarian insufficiency or premature menopause have more years of estrogen deficiency ahead of them and may face increased concerns involving bone health and other long-term consequences.

Unless contraindicated, hormone therapy is often recommended in women with premature menopause or primary ovarian insufficiency until approximately the average age of natural menopause, at which time the treatment plan can be reassessed.

This should not be confused with starting hormone therapy for the first time many years after natural menopause.

They are clinically different situations.

Does HRT Have to Stop at Age 65?

No universal rule requires every woman to discontinue hormone therapy at age 60 or 65.

Some women continue to experience significant vasomotor symptoms well beyond the average age of menopause. Others may have continuing treatment considerations involving bone health or genitourinary symptoms.

The Menopause Society states that hormone therapy does not need to be routinely discontinued solely because a woman has reached age 60 or 65. Extended use can be considered in selected women after individualized counseling and periodic reassessment.

However, the benefit-risk profile changes as women age.

Continued therapy should therefore involve periodic review of cardiovascular risk, breast health, clotting risk, bone health, symptoms, medication dose, route of administration, and whether treatment is still providing a meaningful benefit.

How Long Should a Woman Stay on HRT?

There is no single treatment duration that applies to every woman.

Older advice commonly suggested using hormones for the shortest possible duration, but modern menopause care places greater emphasis on individualized treatment and periodic reassessment.

In its 2025 labeling request, the FDA specifically asked manufacturers to remove the boxed-warning recommendation that menopausal hormone therapy always be used at the lowest effective dose for the shortest amount of time.

That does not mean dose and duration no longer matter.

They remain important parts of risk assessment.

Some women need treatment for several years while vasomotor symptoms are most disruptive. Others continue longer after discussing their individual risks and benefits with their physician.

A reasonable treatment plan asks repeatedly: Is this therapy still helping? Have health risks changed? Is the current formulation and route still appropriate? Can the dose be adjusted? Does the patient still want to continue?

What Happens When HRT Is Stopped?

Menopausal symptoms may return after systemic hormone therapy is discontinued.

The Menopause Society reports that vasomotor symptoms recur in approximately half of women after stopping therapy, and evidence has not clearly established that tapering is superior to abrupt discontinuation for preventing recurrence.

Genitourinary symptoms are different.

Vaginal and urinary changes caused by ongoing estrogen deficiency commonly persist or worsen with time, which means some women continue local vaginal treatment even after systemic hormone therapy is no longer necessary.

HRT Should Be Part of a Larger Midlife Health Evaluation

Hormone therapy can be extremely helpful when used for the right indications, but menopause care should involve more than prescribing hormones.

Midlife is also an important opportunity to evaluate blood pressure, cholesterol, blood sugar, cardiovascular risk, bone health, breast and cervical cancer screening, sleep, exercise, nutrition, alcohol intake, smoking, mental health, sexual health, and body composition.

Many symptoms attributed to “hormone imbalance” overlap with other medical problems.

Fatigue could reflect menopause, but it could also be caused by hypothyroidism, iron deficiency, sleep apnea, depression, medication effects, or another condition.

Weight gain may occur during midlife, but menopausal hormone therapy should not be promoted as a weight-loss treatment.

Brain fog is commonly described during the menopause transition, but hormone therapy is not recommended specifically for prevention of dementia or cognitive decline in women experiencing menopause at the usual age.

Good menopause medicine requires treating the patient rather than automatically attributing every midlife symptom to declining hormones.

How Is an HRT Treatment Plan Selected?

A thoughtful evaluation begins with the clinical picture rather than with a predetermined hormone protocol.

Your physician may consider your menstrual and reproductive history, current symptoms, uterus and ovarian status, personal and family cancer history, cardiovascular history, blood-clotting risk, medications, migraines, liver health, sexual health, bone health, previous hormone treatment, contraceptive needs, and personal goals.

Laboratory testing or additional diagnostic evaluation may be appropriate depending on the situation.

If treatment is chosen, the next decision involves selecting the hormone, route, dose, regimen, and monitoring plan that best fit the patient's needs.

For an overview of the process from consultation through follow-up, read A Patient's Guide to Starting Hormone Replacement Therapy.

Follow-Up Matters

Hormone therapy should not be prescribed once and then forgotten.

Early follow-up allows the physician and patient to review symptom improvement, adverse effects, bleeding patterns, blood pressure, medication adherence, sexual or vaginal symptoms, and whether the treatment is meeting its intended goals.

The dose or delivery method may need to be adjusted.

Women should also remain current with appropriate preventive care and age- and risk-based screening.

New postmenopausal bleeding, significant unexplained bleeding, chest pain, shortness of breath, symptoms suggesting a blood clot or stroke, a new breast finding, or another significant health change requires appropriate medical evaluation rather than simply adjusting hormone medication.

Is HRT Right for Every Woman Going Through Menopause?

No.

Some women have minimal symptoms and do not need medication.

Others prefer nonhormonal treatment.

Some have health conditions that make systemic hormone therapy inappropriate.

And for many women, hormone therapy provides substantial relief and improved quality of life when treatment is selected carefully.

The question should therefore not be simply, “Is HRT good or bad?”

A better question is:

What are the likely benefits and risks of this specific treatment, for this specific woman, at this point in her life?

That is the foundation of individualized menopause care.

Hormone Replacement Therapy for Women in Arizona

At Ask Dr. Hu, hormone therapy begins with an individualized medical evaluation rather than a one-size-fits-all protocol.

We consider your symptoms, medical history, medications, reproductive history, relevant laboratory findings, risk factors, and treatment goals before determining whether hormone therapy is appropriate.

When treatment is prescribed, follow-up care is used to evaluate symptom response, medication tolerance, safety considerations, and whether adjustments are needed over time.

Women throughout Arizona can learn more about our Hormone Replacement Therapy services or explore additional physician-written information in the Hormone Replacement Therapy Resource Center.

Evidence-Based Medical Information

This article is intended to provide balanced, evidence-informed information about menopause hormone therapy rather than to suggest that every woman experiencing menopause should use HRT.

Recommendations and safety information were informed by current resources from the U.S. Food and Drug Administration, The Menopause Society, and the Endocrine Society. Current FDA labeling changes concerning menopausal hormone therapy were also reviewed when this article was updated in August 2026.

Medical evidence and medication labeling continue to evolve. Treatment decisions should always be individualized according to a patient's medical history, symptoms, risk factors, medications, and preferences.

About the Author

Dr. YiQiu Hu, NMD is an Arizona-licensed naturopathic physician and founder of Ask Dr. Hu. His clinical interests include preventive healthcare, hormone care, health optimization, medical weight management, diagnostic evaluation, and individualized laboratory testing.

His approach to hormone therapy emphasizes careful evaluation, evidence-informed prescribing, appropriate laboratory and clinical monitoring, and helping patients understand both the potential benefits and limitations of treatment.

Learn more about Dr. Hu and the physicians at Ask Dr. Hu.

This article is for general educational purposes and does not replace individualized medical advice, diagnosis, or treatment and does not establish a physician-patient relationship.